BRNSBarinthus Biotherapeutics plc.

Nasdaq www.barinthusbio.com


$ 2.09 $ -0.05 (-2.21 %)    

Friday, 24-May-2024 14:39:17 EDT
QQQ $ 454.82 $ 4.29 (0.95 %)
DIA $ 398.57 $ -0.02 (-0.01 %)
SPY $ 530.36 $ 3.48 (0.66 %)
TLT $ 91.26 $ 0.27 (0.3 %)
GLD $ 225.37 $ 0.20 (0.09 %)
$ 2.21
$ 2.23
$ 0.00 x 0
$ 0.00 x 0
$ 2.09 - $ 2.23
$ 1.64 - $ 5.10
19,385
na
85.69M
$ 0.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-20-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-25-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 06-14-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barinthus-bio-to-present-vtp-300-clinical-updates-at-easl-congress-2024

Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations....

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $8 price...

 barinthus-biotherapeutics-q1-eps-040-beats-054-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimat...

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $8 price...

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $8 price...

 infection-focused-barinthus-bios-vtp-200-data-underwhelming-analyst-weighs-on-mixed-perspectives

Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervi...

 hc-wainwright--co-maintains-buy-on-barinthus-biotherapeutics-lowers-price-target-to-8

HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and lowers the price ta...

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-15-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $15 pric...

Core News & Articles

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained we...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION